Trial Profile
An Open-label, Single Arm, Prospective Study to Evaluate the Safety and Anti-hypertensive Efficacy of Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination in Patients With Mild to Moderate Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2022
Price :
$35
*
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Merck & Co
- 12 Sep 2011 New trial record